Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Rydex Europe Advantage Fund Class A (RYAEX)

14.89
Net Asset Value
+2.06%
1 Day
-0.87%
Year-to-Date
Overall Morningstar Rating
Trading-leveraged equity
Style or Category
4.75
Sales Expenses
1.72%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks to provide investment results that correlate, before fees and expenses, to the performance of 125% of the fair value of the STOXX Europe 50  Index. The fund employs as its investment strategy a program of investing in the common stock of companies that are generally within the capitalization range of the underlying index and derivative instruments. It will invest at least 80% of its net assets, plus any borrowings for investment purposes, in securities of companies in the underlying index and derivatives and other instruments whose performance is expected to correspond to that of the underlying index. The fund is non-diversified.

Performance

1 month-7.48% 3 years+5.86%
3 months-10.49% 5 years+5.46%
1 year-16.30% Since inception+1.43%
Data through --

Peer Comparisonvs. Trading-leveraged equity

 RYAEXCategory
Performance 5-yr return+5.46%+16.48%
Expense ratio1.72%2.05%
Risk 5 year sharpe ratio0.38--
Net assets$20.3M$78.9M
Average market cap$108.3B--
Average P/E18.4--
Portfolio turnover608%608%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyRydex Funds
Fund manager & tenureMichael Byrum / 15 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

Cash47.60%
International stock39.70%
Fixed income12.70%
U.S. stock0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Financial service 21.80%
Energy 20.96%
Telecommunication 16.63%
Healthcare 16.00%
Industrial materials 14.03%
Top 10 Holdings
Portfolio weighting
-- 12.31%
NVS Novartis2.61%
NSRGY Nestle2.40%
RHHBY Roche1.99%
HSBC HSBC1.70%
-- 1.55%
SNY Sanofi1.29%
BAYRY Bayer1.20%
TOT Total1.15%
NVO Novo Nordisk1.13%

Partner Offers